Zacks
0
All posts from Zacks
Zacks in Our Research. Your Success.,

Jazz Pharmaceuticals (JAZZ) Posts Q1 Earnings Beat, Updates 2016 Outlook

Jazz Pharmaceuticals, Inc. JAZZ just released its first quarter fiscal 2016 earnings results, posting earnings of $1.87 per share and revenue of $336 million.  

Currently, JAZZ has a Zacks Rank #3 (Hold), but it is subject to change following the release of the company’s latest earnings report. Here are 5 key statistics from this just announced report below.

Jazz Pharmaceuticals:                       

1. Beat earnings estimates. The company posted earnings of $1.87 per share, surpassing the Zacks Consensus Estimate of $1.31 per share. This number excludes $0.68 from non-recurring items.

2. Missed revenue estimates. The company saw revenue figures of $336 million, missing our consensus estimate of $340 million but increasing 8.6% year-over-year.

3. Reported that net product sales increased by 9% to $333.9 million in the first quarter of 2016 compared to the same period in 2015 primarily due to higher net product sales of Xyrem.

4. Updated its full year 2016 guidance. Revenues are now expected to be in the range of $1.490-1.550 billion, total net product sales in the range of $1.482-1.542 billion, and non-GAAP adjusted net income per diluted share in the range of $11.10-11.50.

5. JAZZ was up $0.09, or 0.06%, to $147.91 as of 5:25 PM ET in after-hours trading shortly after its earnings report was released.

Here’s a graph that looks at Jazz Pharmaceuticals’ stock change over time vs. the S&P 500:

Jazz Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on identifying, developing and commercializing innovative products to meet unmet medical needs in neurology and psychiatry. The Company's goal is to build a broad portfolio of products through a combination of internal development and acquisition/in-licensing activities and to utilize our specialty sales force to promote products in our target markets. Based in Palo Alto, California, the Company is committed to working closely with patients, patient advocacy groups and healthcare professionals.

Check back later for our full analysis onJazz Pharmaceuticals’ first quarter earnings report!

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 DaysClick to get this free report >>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
JAZZ PHARMACEUT (JAZZ): Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research